The gist: A recent study found that elderly patients with early-stage, moderate- to high-risk breast cancer don’t benefit from the addition of the drug capecitabine to their post-surgery treatment with the drug ibandronate.
“The use of adjuvant capecitabine in elderly patients with moderate- to high-risk early breast cancer resulted in no improvement in disease-free survival, according to a study presented at the 2014 San Antonio Breast Cancer Symposium.
“The phase III ICE study tested ibandronate, a bisphosphonate, with or without capecitabine in women aged 65 years or older.
“ ‘At 3 years there was no difference in invasive disease-free survival between the treatment arms,’ said study presenter, Gunter von Minckwitz, MD, chairman of the German Breast Group and a professor of gynecology at University of Frankfurt, Germany. ‘After 5 years, the curves seem to slightly separate, but after the curves cross, showing no statistically significant difference.’ ”